Neurocrine Biosciences, Inc（NBIX）の財務NBIXNeurocrine Biosciences, Inc

Neurocrine Biosciences, Inc. (NBIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is VYKAT XR net production sale, accounting for 100.0% of total sales, equivalent to $954.30M. Other significant revenue streams include INGREZZA and CRENESSITY. Understanding this composition is critical for investors evaluating how NBIX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Neurocrine Biosciences, Inc. maintains a gross margin of 95.87%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.95%, while the net margin is 15.06%. These profitability ratios, combined with a Return on Equity (ROE) of 22.09%, provide a clear picture of how effectively NBIX converts its operational activities into shareholder value.

In the context of the broader market, NBIX competes directly with industry leaders such as HALO and BBIO. With a market capitalization of $14.36B, it holds a leading position in the sector. When comparing efficiency, NBIX's gross margin of 95.87% stands against HALO's 77.40% and BBIO's 93.83%. Such benchmarking helps identify whether Neurocrine Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Neurocrine has shown strong financial performance with a gross margin of 95.87% in Q2 2026 and a net income of $144.4 million in the same quarter, indicating solid profitability. Adjusted net income rose to $297 million for Q2 2026, reflecting improved operational efficiency.